U.S. Surgical reduces unfriendly bid for Circon to $17 per share.
This article was originally published in The Gray Sheet
Executive SummaryU.S. SURGICAL REDUCES UNFRIENDLY BID FOR CIRCON TO $17 PER SHARE, citing Circon's disappointing third quarter results. USSC announced Dec. 16 that it is lowering by one dollar its previously announced $18-per-share tender offer for minimally invasive urological and gynecological surgery products manufacturer Circon.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.